Cheap and easy to store, the Oxford-AstraZeneca vaccine has boosted the global fight against coronavirus but fears over cases of rare blood clots and production delays have marred its rollout. Here are five facts about the vaccine.
- Practicality -
The AstraZeneca vaccine costs about £2.50 ($3.40, 2.75 euros) per dose and can be kept at refrigerator temperatures, making it ideal for large-scale vaccination programmes.
The vaccine has been authorised for use in more than 70 countries, AstraZeneca says.
More than 9.2 million jabs have been administered in the European Economic Area, including the EU, Norway, Iceland and Liechtenstein.
- Blood clot fears -
Cases of rare blood clots in vaccinated people have prompted numerous countries to halt or limit rollout.
The European Medicines Agency (EMA) said on March 31 that there had been 62 cases worldwide of a rare clotting condition, cerebral venous sinus thrombosis, 44 of them in the European Economic Area.
Thirty cases of rare blood clotting conditions have been recorded in Britain, and seven people have died.
AstraZeneca said in mid-March that there was "no evidence" of higher risk of blood clots from its vaccine.
But as a result, Denmark and Norway have paused vaccinations.
Some countries rejected a batch of vaccines after an Austrian nurse died from multiple thrombosis following vaccination and another person suffered a pulmonary embolism.
Many countries have resumed the vaccine's use only for older people, aged 55 and above, because the blood clots affected younger people.
These include France, Canada, Germany, the Netherlands, Finland, Iceland and Sweden, as well as Canada.
The EMA said March 18 that the AstraZeneca jab is safe and effective.
Some countries including Estonia, Latvia, Lithuania, Luxembourg, Portugal, Italy, Ireland and Spain resumed full rollout after reassurance from the EMA.
The EMA is expected to announce updated advice on April 7.
- Delays in delivery -
The vaccine was first approved for use in the general population in Britain, which ordered 100 million doses.
In the EU, delivery delays have led to strong criticism of the Anglo-Swedish firm.
AstraZeneca announced in January it could only deliver one third of the 120 million doses initially promised to the 27 member states in the first quarter.
In March, Italy blocked the export of 250,000 doses to Australia, citing "persistent shortage" and "delays in supply", a move backed by the European Commission.
EU member states were set to receive 29.8 million doses of the AstraZeneca vaccine by the end of March, the European Commission said.
- Chimpanzees -
The vaccine is "virus-vectored", meaning it is a version of a virus that normally infects chimpanzees and has been modified with a portion of the Covid-19 coronavirus called the "spike protein" to fire the immune system.
Once in human cells, the vaccine should help stimulate the production of antibodies that recognise the virus.
The vaccine is "safe and effective", according to data published by The Lancet medical journal in December, with only one of 23,754 volunteers who participated in the trials experiencing "possibly-related severe side effects".
This was a case of a rare neurological condition that forced the temporary suspension of trials.
- Result confusion -
AstraZeneca announced in interim findings in November that its vaccine was on average 70 percent effective, compared with more than 90 percent for Pfizer/BioNTech and Moderna.
The efficacy of the AstraZeneca vaccine was 90 percent for volunteers who first received only a half dose and then a full dose one month later, but only 62 percent for those in another group who were vaccinated with two full doses one month apart.
The injection of a half dose was conducted by accident, raising criticism over the robustness of the results and prompting the company to conduct additional studies.
A more recent study conducted by health authorities in England has shown protection of between 60 percent and 73 percent against symptoms in people over 70 years old, with a single dose.
Last month, AstraZeneca announced a US trial showed 79 percent effectiveness but then revised this to 76 percent after the US authorities raised concerns that some results were outdated.
The US has not yet approved its use domestically.
ETX Studio
Tue Apr 06 2021
AstraZeneca announced in interim findings in November that its vaccine was on average 70 per cent effective, compared with more than 90 per cent for Pfizer/BioNTech and Moderna. ETXStudiopic
Program larian disertai pelancong berpakaian tidak sopan bukan anjuran kerajaan Johor
Program larian yang didakwa disertai pelancong asing berpakaian kurang sopan dan mempromosi budaya songsang lesbian, gay, biseksual serta transgender (LGBT) bukan anjuran kerajaan negeri.
Imigresen serbu pusat karaoke, 49 GRO dan pelanggan ditahan
JIM Perak menyerbu empat premis pusat hiburan karaoke yang menawarkan GRO warga Myanmar dengan bayaran antara RM450 hingga RM600 di sekitar bandar raya ini, malam tadi.
AWANI Ringkas: Pendatang asing tanpa izin | Kekecohan di Wisma Transit
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Tumpuan Ahad – 06 Oktober 2024
Ikuti rangkuman berita utama yang menjadi tumpuan di Astro AWANI.
Polis siasat dakwaan buli di sekolah berasrama penuh di KL
Polis sedang menjalankan siasatan berhubung dakwaan berlaku kejadian buli membabitkan anak seorang penyanyi dan beberapa individu lain di sebuah sekolah berasrama penuh di ibu negara.
Peruntukan tebatan banjir Sungai Damansara diluluskan, kurangkan risiko di Sungai Buloh
Peruntukan berjumlah RM481 juta bagi Projek Tebatan Banjir Sungai Damansara telah diluluskan sebagai usaha mengurangkan risiko banjir di kawasan Parlimen Sungai Buloh.
AWANI 7:45 [05/10/2024] – Tunggu perkenan Majlis Raja-Raja | Inflasi dan gaji jadi tumpuan | Kes terpencil | Zionis terus angkuh
- Tiga negeri fatwakan GISB sesat, siasatan libat 10 peruntukan
- Belanjawan 2025 tumpu isu inflasi dan naik gaji
- Kekecohan libat warga Palestin mungkin sebab stress, ATM tangani dengan profesional
- Gaza hancur lebur, Beirut hampiri kemusnahan
- Belanjawan 2025 tumpu isu inflasi dan naik gaji
- Kekecohan libat warga Palestin mungkin sebab stress, ATM tangani dengan profesional
- Gaza hancur lebur, Beirut hampiri kemusnahan
Pekebun boleh kemuka tuntutan akibat serangan haiwan liar
Pekebun yang mengalami kerugian hasil tanaman akibat ancaman haiwan liar boleh mengemukakan tuntutan pampasan terhadap kerosakan yang berlaku.
AWANI Ringkas: GISB Holdings | Kes tembakan di Song | PR1MA
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Lelaki rugi RM224,000 terperdaya skim pelaburan tidak wujud
Seorang lelaki warga tempatan berputih mata apabila kerugian RM224,000 setelah terperdaya dengan skim pelaburan tidak wujud yang diiklankan menerusi aplikasi WhastApp.
Vaksin COVID-19: Thailand mulakan kembali program vaksin AstraZeneca
Perdana Menteri Prayuth Chan O-Cha dan anggota kabinet antara yang terawal menerima suntikan AstraZeneca.
Thailand terima kumpulan pertama vaksin COVID-19, suntikan dijadual bermula minggu ini
Thai Airways International yang mengangkut 200,000 dos vaksin itu mendarat di Lapangan Terbang Antarabangsa Suvarnabumi pada 10.05 pagi (waktu tempatan).
Thailand mulakan program vaksinasi minggu ini
Thailand akan menerima kumpulan pertama 200,000 daripada 2 juta dos vaksin yang dibangunkan syarikat farmaseutikal China itu hari ini.
Thailand tempah tambahan 35 juta dos vaksin COVID-19
Thailand telah menempah tambahan 35 juta dos vaksin COVID-19, menjadikan jumlah pembelian 61 juta dos daripada firma farmaseutikal multinasional Britain-Sweden, Oxford-AstraZeneca.